Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prithviraj Bose

Showing results (51-60 of 224) with videos related to

Pageof 23
Sort By:
Leukemia & Lymphoma|February 7, 2019
Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'Prithviraj Bose, Lisa S Chen, Varsha Gandhi
Therapeutic Advances in Hematology|August 15, 2022
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerationsAlexandra R Lovell, Nadya Jammal, Prithviraj Bose
Expert Review of Hematology|December 14, 2025
Current treatments, practical management, and emerging investigational therapies for myelofibrosisSrinivas Tantravahi, Firas El Chaer, Prithviraj Bose
Current Treatment Options in Oncology|March 14, 2017
Treatment of Relapsed/Refractory Acute Myeloid LeukemiaPrithviraj Bose, Pankit Vachhani, Jorge E Cortes
Expert Opinion on Investigational Drugs|May 8, 2013
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesPrithviraj Bose, Gary L Simmons, Steven Grant
Expert Opinion on Investigational Drugs|April 27, 2017
Investigational Janus kinase inhibitors in development for myelofibrosisPrithviraj Bose, Abdallah Abou Zahr, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|May 25, 2023
An update on the efficacy of Venetoclax for chronic lymphocytic leukemiaAlexandra R Lovell, Jacki Sawyers, Prithviraj Bose
Physiological Genomics|May 15, 2014
Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AMLPankit Vachhani, Prithviraj Bose, Mohamed Rahmani, et al.
The New England Journal of Medicine|May 15, 2009
Bevacizumab in hereditary hemorrhagic telangiectasiaPrithviraj Bose, Jennifer L Holter, George B Selby
Expert Opinion on Drug Metabolism & Toxicology|October 1, 2016
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower dosesPrithviraj Bose, Varsha V Gandhi, Michael J Keating
Pageof 23

Showing results (51-60 of 224) with videos related to

Sort By:
Pageof 23
Leukemia & Lymphoma|February 7, 2019
Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'Prithviraj Bose, Lisa S Chen, Varsha Gandhi
Therapeutic Advances in Hematology|August 15, 2022
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerationsAlexandra R Lovell, Nadya Jammal, Prithviraj Bose
Expert Review of Hematology|December 14, 2025
Current treatments, practical management, and emerging investigational therapies for myelofibrosisSrinivas Tantravahi, Firas El Chaer, Prithviraj Bose
Current Treatment Options in Oncology|March 14, 2017
Treatment of Relapsed/Refractory Acute Myeloid LeukemiaPrithviraj Bose, Pankit Vachhani, Jorge E Cortes
Expert Opinion on Investigational Drugs|May 8, 2013
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesPrithviraj Bose, Gary L Simmons, Steven Grant
Expert Opinion on Investigational Drugs|April 27, 2017
Investigational Janus kinase inhibitors in development for myelofibrosisPrithviraj Bose, Abdallah Abou Zahr, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|May 25, 2023
An update on the efficacy of Venetoclax for chronic lymphocytic leukemiaAlexandra R Lovell, Jacki Sawyers, Prithviraj Bose
Physiological Genomics|May 15, 2014
Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AMLPankit Vachhani, Prithviraj Bose, Mohamed Rahmani, et al.
The New England Journal of Medicine|May 15, 2009
Bevacizumab in hereditary hemorrhagic telangiectasiaPrithviraj Bose, Jennifer L Holter, George B Selby
Expert Opinion on Drug Metabolism & Toxicology|October 1, 2016
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower dosesPrithviraj Bose, Varsha V Gandhi, Michael J Keating
Pageof 23